(Q36512574)

English

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

scientific article published on July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach (English)

1 reference

Europe PubMed Central

14 August 2017

1 reference

based on heuristic

inferred from title

author name string

Michael Koutsilieris

1

1 reference

Europe PubMed Central

14 August 2017

John Bogdanos

2

1 reference

Europe PubMed Central

14 August 2017

Constantine Milathianakis

3

1 reference

Europe PubMed Central

14 August 2017

Peter Dimopoulos

4

1 reference

Europe PubMed Central

14 August 2017

Theodoros Dimopoulos

5

1 reference

Europe PubMed Central

14 August 2017

Dimitrios Karamanolakis

6

1 reference

Europe PubMed Central

14 August 2017

Antonis Halapas

7

1 reference

Europe PubMed Central

14 August 2017

Roxane Tenta

8

1 reference

Europe PubMed Central

14 August 2017

Haralampos Katopodis

9

1 reference

Europe PubMed Central

14 August 2017

Effie Papageorgiou

10

1 reference

Europe PubMed Central

14 August 2017

Nea Pitulis

11

1 reference

Europe PubMed Central

14 August 2017

Nikos Pissimissis

12

1 reference

Europe PubMed Central

14 August 2017

Peter Lembessis

13

1 reference

Europe PubMed Central

14 August 2017

Antigone Sourla

14

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 July 2006

1 reference

Europe PubMed Central

14 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

14 August 2017

15

1 reference

Europe PubMed Central

14 August 2017

7

1 reference

Europe PubMed Central

14 August 2017

795-804

1 reference

Europe PubMed Central

14 August 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Mechanisms of tumor metastasis to the bone: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

The prostate: diagnostic evaluation of metastatic disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Mechanisms of Osteoblastic Metastases: Role of Endothelin-1

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Effects of human prostatic mitogens on rat bone cells and fibroblasts

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Skeletal metastases in advanced prostate cancer: cell biology and therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

The role of IL-6 type cytokines and their receptors in bone.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Regulation of interleukin-6 expression in human osteoblastic cells in vitro

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Diagnosing and treating small-cell carcinomas of prostatic origin

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.7.795

21 January 2018

Identifiers

10.1517/13543784.15.7.795

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36512574&oldid=1636492643"